Basel Medical Group Ltd (BMGL) Fair Value 2026

BMGL · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (10/100)

Quick Summary — As of 2026-08-28, Basel Medical Group Ltd (BMGL) trades at $5.24. QOC: 4.8/10. Value Trap Risk: 10/100 (SAFE). 0/13 models active.

Key Facts

Ticker
BMGL
Price
$5.24
Quality Score
4.8/10
Value Trap Risk
10/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give BMGL?

0 Intrinsic Value Models vs. Current Price ($5.24)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Basel Medical Group Ltd (BMGL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Basel Medical Group Ltd currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BMGL?

0 of 13 models are currently active for BMGL. See which stocks rank higher →

How Does BMGL Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, BMGL ranks #51 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Medical Care Facilities Stocks →

Basel Medical Group Ltd operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BMGL a Value Trap?

CirclFi's Value Trap algorithm assigns BMGL a score of 10/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Basel Medical Group Ltd. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Basel Medical Group Ltd earns a quality score of 4.8/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BMGL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Basel Medical Group Ltd Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

11 related Medical Care Facilities stocks with 13-model coverage

BICXBioCorRx Inc.QOC 4.9PIIIP3 Health Partners Inc.QOC 4.7SNDASonida Senior Living, Inc.QOC 5.2CMPSCOMPASS Pathways plcQOC 4.5ADIAAdia Med IncQOC 5.2HLYKHealthLynked Corp.QOC 4.1OPCHOption Care Health, Inc.QOC 8.4FMSFresenius Medical Care AGQOC 7.3MCTACharming Medical LimitedQOC 6.1ADUSAddus HomeCare CorporationQOC 8.9NHCNational HealthCare CorporationQOC 8.7

Read investment analysis: BICX · PIII · SNDA · CMPS · ADIA · HLYK · OPCH · FMS · MCTA · ADUS · NHC

Which Other Stocks Have a Similar Quality Score to BMGL?

7 companies across all industries closest to BMGL’s Quality of Company score of 4.8/10.

INIOInnio N.V.QOC 4.8ELVRElevra Lithium LimitedQOC 4.8MFONMobivity Holdings Corp.QOC 4.8TAAGThe Awareness Group IncQOC 4.8RAPPRapport Therapeutics, Inc.QOC 4.8GECCGreat Elm Capital Corp.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: INIO · ELVR · MFON · TAAG · RAPP · GECC · NVDA

Where Does BMGL Sit in CirclFi's Medical Care Facilities Rankings?

BMGL is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About Basel Medical Group Ltd’s Valuation?

What is Basel Medical Group Ltd's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Basel Medical Group Ltd (BMGL). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BMGL overvalued or undervalued right now?

At $5.24, 0 of 0 active models suggest BMGL may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Basel Medical Group Ltd's business model in Medical Care Facilities.

What does a Quality of Company score of 4.8 mean for BMGL?

Basel Medical Group Ltd's QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BMGL?

CirclFi analyzes BMGL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BMGL a value trap in 2026?

Basel Medical Group Ltd's Value Trap score is 10/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Basel Medical Group Ltd (BMGL) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BMGL/ · Methodology
Primary sources for this BMGL valuation
  • Financial statements: Basel Medical Group Ltd 10-K and 10-Q filings on SEC EDGAR (CIK 0002004489) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BMGL as of ; valuations recomputed .